New Treatment, Libtayo (cemiplimab-rwlc) Injection, Approved for Squamous Cell Carcinoma

MONDAY, Oct. 1, 2018 — Libtayo (cemiplimab-rwlc) injection has been approved by the U.S. Food and Drug Administration to treat advanced squamous cell carcinoma (CSCC), the agency said in a news release.
The drug is from a class of medications…
Source: Topamax